Table 6.
Clinical outcomes after 4th dose of vaccination.
| Author | Side effects | COVID-19 infection | 4th dose recommended (yes/no) |
|---|---|---|---|
| Caillard | 0 (0%) | 1 (1%) | Yes |
| Karaba | NR | NR | No |
| Kamar | 0 (0%) | 0 (0%) | Yes |
| Teles | NR | NR | Yes |
| Mitchell | NR | NR | Yes |
| Osmanodja | 0 (0%) | NR | Yes |
| Aikawa | No serious adverse events | NR | Yes |
| Mrak | No serious adverse events | 1 (2.7%) | Yes |
| Ntanasis-stathopoulos | NR | 0 (0%) | Yes |
| Perrier | NR | NR | Yes |
| Assawasaksakul | No serious adverse events | NR | Yes |
| Gössi | NR | 1 (14.2%) | Yes |
| Harberts | No serious adverse events | NR | Yes |
| Benjamini | No serious adverse events | 14 (21%) |
Yes |
| Midtvedt | No serious adverse events | NR | Yes |
| Peled | NR | NR | Yes |
| Thomson | NR | NR | No |
| Busà | NR | NR | Yes |
| Brandstetter | No serious adverse events | NR | Yes |
| Hod | No serious adverse events | 9 | Yes |
| Bjorlykke | No serious adverse events | 35 (7% of 491) | Yes |
| Lamacchia | NR | 2 | Yes |
| Affeldt | NR | NR | Yes/No |
| Davidov | No serious adverse events | 9 (18%) | Yes |
NR, not reported.